Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 195

1.

Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain.

Hussmann GP, Turner JR, Lomazzo E, Venkatesh R, Cousins V, Xiao Y, Yasuda RP, Wolfe BB, Perry DC, Rezvani AH, Levin ED, Blendy JA, Kellar KJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):441-50. doi: 10.1124/jpet.112.198085. Epub 2012 Aug 16.

PMID:
22899752
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain.

Hussmann GP, DeDominicis KE, Turner JR, Yasuda RP, Klehm J, Forcelli PA, Xiao Y, Richardson JR, Sahibzada N, Wolfe BB, Lindstrom J, Blendy JA, Kellar KJ.

J Neurochem. 2014 May;129(4):721-31. doi: 10.1111/jnc.12653. Epub 2014 Feb 7.

PMID:
24422997
[PubMed - indexed for MEDLINE]
3.

The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.

Paterson NE, Min W, Hackett A, Lowe D, Hanania T, Caldarone B, Ghavami A.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1455-64. doi: 10.1016/j.pnpbp.2010.07.037. Epub 2010 Aug 11.

PMID:
20708056
[PubMed - indexed for MEDLINE]
4.

Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380.

Caldarone BJ, Wang D, Paterson NE, Manzano M, Fedolak A, Cavino K, Kwan M, Hanania T, Chellappan SK, Kozikowski AP, Olivier B, Picciotto MR, Ghavami A.

Psychopharmacology (Berl). 2011 Sep;217(2):199-210. doi: 10.1007/s00213-011-2271-y. Epub 2011 Apr 13.

PMID:
21487659
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal.

Turner JR, Wilkinson DS, Poole RL, Gould TJ, Carlson GC, Blendy JA.

Neuropsychopharmacology. 2013 Sep;38(10):2035-47. doi: 10.1038/npp.2013.105. Epub 2013 Apr 29.

PMID:
23624742
[PubMed - indexed for MEDLINE]
6.

Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats.

Levin ED, Rezvani AH, Xiao Y, Slade S, Cauley M, Wells C, Hampton D, Petro A, Rose JE, Brown ML, Paige MA, McDowell BE, Kellar KJ.

J Pharmacol Exp Ther. 2010 Mar;332(3):933-9. doi: 10.1124/jpet.109.162073. Epub 2009 Dec 10.

PMID:
20007754
[PubMed - indexed for MEDLINE]
Free Article
7.

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE.

Neuropharmacology. 2007 Mar;52(3):985-94. Epub 2006 Dec 8.

PMID:
17157884
[PubMed - indexed for MEDLINE]
8.

Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them.

Xiao Y, Fan H, Musachio JL, Wei ZL, Chellappan SK, Kozikowski AP, Kellar KJ.

Mol Pharmacol. 2006 Oct;70(4):1454-60. Epub 2006 Jul 20.

PMID:
16857741
[PubMed - indexed for MEDLINE]
Free Article
9.

Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.

Ortiz NC, O'Neill HC, Marks MJ, Grady SR.

Nicotine Tob Res. 2012 Jun;14(6):711-9. doi: 10.1093/ntr/ntr284. Epub 2012 Jan 12.

PMID:
22241831
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats.

Johnson JE, Slade S, Wells C, Petro A, Sexton H, Rezvani AH, Brown ML, Paige MA, McDowell BE, Xiao Y, Kellar KJ, Levin ED.

Psychopharmacology (Berl). 2012 Jul;222(2):269-76. doi: 10.1007/s00213-012-2642-z.

PMID:
22297831
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.

Rollema H, Shrikhande A, Ward KM, Tingley FD 3rd, Coe JW, O'Neill BT, Tseng E, Wang EQ, Mather RJ, Hurst RS, Williams KE, de Vries M, Cremers T, Bertrand S, Bertrand D.

Br J Pharmacol. 2010 May;160(2):334-45. doi: 10.1111/j.1476-5381.2010.00682.x. Epub 2010 Mar 22.

PMID:
20331614
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.

George O, Lloyd A, Carroll FI, Damaj MI, Koob GF.

Psychopharmacology (Berl). 2011 Feb;213(4):715-22. doi: 10.1007/s00213-010-2024-3. Epub 2010 Oct 6.

PMID:
20924754
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats.

Bito-Onon JJ, Simms JA, Chatterjee S, Holgate J, Bartlett SE.

Addict Biol. 2011 Jul;16(3):440-9. doi: 10.1111/j.1369-1600.2010.00309.x. Epub 2011 Mar 11.

PMID:
21392178
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The antinociceptive effects of nicotinic partial agonists varenicline and sazetidine-A in murine acute and tonic pain models.

AlSharari SD, Carroll FI, McIntosh JM, Damaj MI.

J Pharmacol Exp Ther. 2012 Sep;342(3):742-9. doi: 10.1124/jpet.112.194506. Epub 2012 Jun 7.

PMID:
22678099
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex.

Zhang X, Gong ZH, Fasth KJ, Långström B, Nordberg A.

Neurochem Int. 1998 May-Jun;32(5-6):435-41.

PMID:
9676742
[PubMed - indexed for MEDLINE]
16.

Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration.

Liu X.

Psychopharmacology (Berl). 2013 Nov;230(2):203-13. doi: 10.1007/s00213-013-3145-2. Epub 2013 May 28.

PMID:
23712602
[PubMed - indexed for MEDLINE]
17.

Effects of chronic sazetidine-A, a selective α4β2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats.

Rezvani AH, Cauley M, Xiao Y, Kellar KJ, Levin ED.

Psychopharmacology (Berl). 2013 Mar;226(1):35-43. doi: 10.1007/s00213-012-2895-6. Epub 2012 Oct 26.

PMID:
23100170
[PubMed - indexed for MEDLINE]
18.

Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.

Metaxas A, Al-Hasani R, Farshim P, Tubby K, Berwick A, Ledent C, Hourani S, Kitchen I, Bailey A.

Neuropharmacology. 2013 Aug;71:228-36. doi: 10.1016/j.neuropharm.2013.03.023. Epub 2013 Apr 11.

PMID:
23583933
[PubMed - indexed for MEDLINE]
19.

Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline.

Turner JR, Castellano LM, Blendy JA.

Nicotine Tob Res. 2011 Jan;13(1):41-6. doi: 10.1093/ntr/ntq206. Epub 2010 Nov 22.

PMID:
21097981
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT.

J Med Chem. 2005 May 19;48(10):3474-7.

PMID:
15887955
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk